Denali Therapeutics (DNLI)Director sold ~$871K
Steve E. Krognes, Director at Denali Therapeutics, sold ~$871K of Denali Therapeutics shares.
- ~$871K
- Approx. value · 30K sh @ $29.03
- 29K
- Holds after · shares reported
- Traded
- Sep 30, 2024
- Filed
- Oct 2, 2024
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
- Sep 30, 2024 · this disclosureInsiderDirector sold ~$871K of DNLI shares in the open market
What came next
- Oct 18, 2024InsiderCEO sold ~$1.11M of DNLI shares in the open market
- Nov 1, 2024InsiderDirector sold ~$83K of DNLI shares in the open market
- Nov 7, 2024Insider · 2 peopleInsiders: 4 sales (~$496K)
- Nov 11, 2024Insider · 1 personInsiders: 2 sales (~$1.9M)
- Dec 31, 2024InsiderDirector sold ~$608K of DNLI shares in the open market
- Jan 2, 2025InsiderDirector sold ~$64K of DNLI shares in the open market
- Jan 6, 2025Insider · 3 peopleInsiders: 3 sales (~$1.1M)
- Jan 7, 2025Insider · 4 peopleInsiders: 4 sales (~$350K)
How to read SEC Form 4
Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.
Full guide: What is an SEC Form 4?
What else is on file for Denali Therapeutics
OQRO holds no insider, Congress, fund or contract record for Denali Therapeutics dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its DNLI page.
Other recent filings by Steve E. Krognes, Director
- SEC Form 4 at Denali Therapeutics (DNLI)Jan 9, 2025
- SEC Form 4 at Denali Therapeutics (DNLI)Jan 3, 2025
The full history of Steve E. Krognes, Director is on the profile page.
How this filing works
Other disclosures at Denali Therapeutics
- SEC Form 13F-HRFeb 17, 2026
- SEC Form 13F-HRFeb 13, 2026
- SEC Form 4Aug 15, 2025
- SEC Form 4Aug 15, 2025
- SEC Form 4Aug 15, 2025
- SEC Form 4Jul 11, 2025
Everything OQRO holds on this company is on its DNLI page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO Pro is a paid subscription. You see the price before you pay
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data